Tandem Diabetes Care (Nasdaq:TNDM) announced that a study of adults with type 2 diabetes supported its automated insulin delivery system.
The study evaluated adults with type 2 diabetes using the t:slim X2 insulin pump with Control-IQ technology. Patients achieved improvement in all clinical endpoints with the technology, which currently does not hold approval for type 2 diabetes.
Data demonstrated safety during six weeks of use. It also presented substantial improvements in time in range and mean glucose related to a reduction in hyperglycemia. Tandem reported no increase in continuous glucose monitor (CGM)-measured hypoglycemia.
Both users of multiple daily injections (MDI) and basal insulin-only showed similar levels of improvement. According to a news release, participants indicated a high level of satisfaction with the Tandem system.
Get the full story at our sister site, Drug Delivery Business News.